Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

Psychopharmacology (Berl). 1997 Aug;132(4):396-401. doi: 10.1007/s002130050361.


Amisulpride is a substituted benzamide with high selectivity for dopaminergic D2 and D3 receptors. This study compared 800 mg/day amisulpride and 20 mg/day haloperidol in patients with acute exacerbations of schizophrenia. This multicenter, double-blind trial involved 191 patients allocated, after a 1 to 7-day wash-out period, to amisulpride (n = 95) or haloperidol (n = 96) for 6 weeks. Improvement of mean BPRS total score was 48% for amisulpride and 38% for haloperidol (NS), whereas improvement in the Negative PANSS subscale was greater in the amisulpride group (37%) compared to haloperidol (24%) (P = 0.038). CGI scores showed a higher number of responders in the amisulpride (62%) than in the haloperidol group (44%) (P = 0.014). More extrapyramidal symptoms measured with the Simpson-Angus scale were provoked in the haloperidol group (P = 0.0009). Amisulpride is at least as effective as haloperidol in the treatment of acute exacerbations of schizophrenia, and is more effective in the treatment of negative symptoms whilst causing less parkinsonism.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Akathisia, Drug-Induced / etiology
  • Amisulpride
  • Antipsychotic Agents / therapeutic use*
  • Brief Psychiatric Rating Scale
  • Double-Blind Method
  • Female
  • Haloperidol / therapeutic use*
  • Humans
  • Male
  • Movement Disorders / etiology
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Sulpiride / analogs & derivatives*
  • Sulpiride / therapeutic use


  • Antipsychotic Agents
  • Sulpiride
  • Amisulpride
  • Haloperidol